rac-opaviraline | 910304-26-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: rac-opaviraline
• 英文别名: isopropyl 2-ethyl-7-fluoro-3-oxo-3,4-dihydroquinoxaline-1(2H)-carboxylate；opaviraline；1(2H)-Quinoxalinecarboxylic acid, 2-ethyl-7-fluoro-3,4-dihydro-3-oxo-, 1-methylethyl ester, (2S)-；propan-2-yl 2-ethyl-7-fluoro-3-oxo-2,4-dihydroquinoxaline-1-carboxylate
• CAS: 910304-26-6
• 化学式: C₁₄H₁₇FN₂O₃
• 分子量: 280.299
• InChiKey: KELNNWMENBUHNS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  58.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  isopropyl 4-benzyl-2-ethyl-7-fluoro-3,4-dihydro-3-oxoquinoxaline-1(2H)-carboxylate 在 N-溴代丁二酰亚胺(NBS) 、 偶氮二异丁腈 作用下， 以 氯苯 为溶剂， 反应 8.0h， 以59%的产率得到rac-opaviraline
  参考文献：
  名称：

  Highly Efficient Synthesis of Quinoxalinone-N-oxide via Tandem Nitrosation/Aerobic Oxidative C–N Bond Formation

  摘要：

  An efficient method for constructing quinoxalinone-N-oxides from cyanoacetanilides has been developed. This transformation can be achieved using inexpensive reagents and molecular oxygen under mild conditions, thus offering a practical pathway to quinoxalinone-containing pharmaceuticals such as ataquimast and opaviraline.

  DOI：

  10.1021/ol202760c

文献信息

• Visible-light-accelerated amination of quinoxalin-2-ones and benzo[1,4]oxazin-2-ones with dialkyl azodicarboxylates under metal and photocatalyst-free conditions
  作者：Jaume Rostoll-Berenguer、Murta Capella-Argente、Gonzalo Blay、José R. Pedro、Carlos Vila

  DOI：10.1039/d1ob01157j

  日期：——

  A direct sp3 C–H amination of cyclic amines (dihydroquinoxalinones and dihydrobenzoxazinones) with dialkyl azo dicarboxylates accelerated by visible-light irradiation under metal and photocatalyst-free conditions is described. This protocol features very mild reaction conditions for the synthesis of aminal quinoxaline and benzoxazine derivatives with good to high yields (up to 99%). These aminal derivatives

  描述了在金属和无光催化剂条件下通过可见光照射加速的环胺（二氢喹喔啉酮和二氢苯并恶嗪酮）与偶氮二羧酸二烷基酯的直接 sp 3 C-H 胺化。该协议具有非常温和的反应条件，用于合成氨基喹喔啉和苯并恶嗪衍生物，产率从好到高（高达 99%）。这些缩醛胺衍生物代表了用于不同合成 quinoxalin-2-one 衍生物的通用构件。
• Electrochemical Hydroalkylation of Quinoxalin‐2(1 <i>H</i> )‐ones with Alkyl Halides
  作者：Zhihong Qiu、Xianting Huang、Jintao Wu、Zhong‐Quan Liu

  DOI：10.1002/adsc.202201241

  日期：2023.2.7

  We reported herein an electrochemically reductive alkylation, allylation and propargylation of quinoxalin-2(1H)-ones with haloalkanes. In an undivided cell, treatment of quinoxalin-2(1H)-ones and alkyl halides with constant current, a wide range of 3-alkylated-3,4-dihydroquinoxalin-2(1H)-one and its derivatives can be isolated in 25–87% yields.

  我们在此报道了喹喔啉-2(1 H )-酮与卤代烷的电化学还原烷基化、烯丙基化和炔丙基化反应。在未分隔的细胞中，恒流处理喹喔啉-2(1 H )-酮和卤代烷，可分离出多种 3-烷基化-3,4-二氢喹喔啉-2(1 H )-酮及其衍生物收益率为 25–87%。
• Long acting compositions comprising zidovudine and lamivudine
  申请人：Sen Himadri

  公开号：US20050175694A1

  公开（公告）日：2005-08-11

  A pharmaceutical composition in the form of a tablet for controlled release of active ingredient(s) comprises lamivudione, zidovudine or combination of lamivudine and zidovudine or their pharmaceutically acceptable derivatives, and a mixture of hydrophilic polymers selected from the group consisting of at least one hydroxypropyl methylcellulose, at least one sodium alginate and at least one guar gum as controlled release matrix and a pharmaceutically acceptable calcium salt as a matrix stabilizer. The composition may also contain one or more of a water soluble and/or water dispersible diluent, wherein the quantities of the hydrophilic polymers, the calcium salt and water soluble and/or water dispersible diluents are such that the therapeutically effective active ingredient(s) is released at a rate suitable for once daily administration of the pharmaceutical composition. The tablets may be coated with a water soluble polymeric film coat.

  一种用于控制释放活性成分的片剂形式的药物组合物包含拉米夫定、齐多夫定或拉米夫定和齐多夫定的组合物或它们的药学上可接受的衍生物，以及从至少一种羟丙基甲基纤维素、至少一种海藻酸钠和至少一种瓜尔胶组成的组中选出的亲水性聚合物混合物作为控制释放基质和药学上可接受的钙盐作为基质稳定剂。该组合物还可含有一种或多种水溶性和/或水分散性稀释剂，其中亲水性聚合物、钙盐和水溶性和/或水分散性稀释剂的用量应使治疗有效活性成分的释放速度适合每日服用一次该药物组合物。片剂可包覆水溶性聚合物薄膜衣。
• LONG ACTING COMPOSITIONS COMPRISING ZIDOVUDINE AND/OR LAMIVUDINE
  申请人：Lupin Limited

  公开号：EP1501521B1

  公开（公告）日：2007-05-02
• SOLID ORAL DOSAGE FORMS OF LAMIVUDINE WITH ISOMALT
  申请人：Hetero Research Foundation

  公开号：EP2435052B1

  公开（公告）日：2015-07-15